Antibody-based proteomics: Analysis of signaling networks using reverse protein arrays

FEBS Journal

Volumn 276, Issue 23, 2009, Pages 6871-6879

  Voshol, Hans ^a   Ehrat, Markus ^b   Traenkle, Jens ^b   Bertrand, Eric ^a   Van Oostrum, Jan ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Zeptosens AG   (Switzerland)

Author keywords

Antibodies; Pathways; Phosphoproteomics; Protein arrays; Signalling networks

Indexed keywords

ANTIBODY; ERLOTINIB; GEFITINIB; IMATINIB; PROTEIN KINASE;

DEREGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

ANTIBODIES; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN KINASES; PROTEOMICS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 70449707621     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07395.x     Document Type: Review

References (28)

1. Blume-Jensen P Hunter T (2001) Oncogenic kinase signaling. Nature 411, 355 365.
2. Ohashi PS (2002) T-cell signaling and autoimmunity; molecular mechanisms of disease. Nat Rev Immunol 2, 427 438.
3. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4, 682 690.
4. Sevecka M MacBeath G (2006) State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods 3, 825 831.
5. Cho C, Labow M, Reinhardt M, van Oostrum J Peitsch MC (2006) The application of systems biology to drug discovery. Curr Opin Chem Biol 10, 294 302.
6. Jia J, Zhu F, Ma X, Cao ZW, Li YX Chen YZ (2009) Mechanisms of drug combinations:interactions and network perspectives. Nat Rev Drug Discov 8, 111 128.
7. Van Oostrum J, Calonder C, Rechsteiner D, Ehrat M, Mestan J, Fabbro D Voshol H (2009) Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin Appl 3, 412 422.
8. Pawaletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF III. Liotta LA (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981 1989.
9. Pawlak M, Schick E, Bopp MA, Schneider MJ, Orozlan P Ehrat M (2002) Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2, 383 393.
10. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB et al. (2005) Use of reverse phase protein microarrays and reference standard develoment for moilecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4, 346 355.
11. Fishman MC Porter JA (2005) A new grammar for drug discovery. Nature 437, 491 493.
12. Butcher EC, Berg EL Kunkel EJ (2004) Systems biology in drug discovery. Nat Biotechnol 22, 1253 1259.
13. Apic G, Ignjatovic T, Boyer S Russel RB (2005) Illuminating drug discovery with biological pathways. FEBS Lett 579, 1872 1877.
14. Araujo RP, Liotta LA Petricoin EF (2007) Proteins, drug targets and the mechanisms they control: the simple truth about complex analysis. Nat Rev Drug Discov 6, 871 880.
15. Zhang J, Yang PL Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9, 28 39.
16. Davies SP, Reddy H, Caivano M Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95 105.
17. Bain J, Plater L, Elliot M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JSC, Alessi DR Cohen P (2007) The selectivity of protein kinase inhibitors. a further update. Biochem J 408, 297 315.
18. Manning G, Whyte DB, Martinez R, Hunter T Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 1912 1934.
19. Daub H, Godl K, Brehmer D, Klebl B Müller G (2004) Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev Technol 2, 215 224. (Pubitemid 38647431)
20. Petrelli A Giordano S (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 15, 422 432.
21. Mendes KN, Nicorici D, Cogdell D, Tabus I, Yli-Harja O, Guerra R, Hamilton SR Zhang W (2007) Analysis of signaling pathways in 90 cancer cell lines by protein lysate arrays. J Proteome Res 6, 2753 2767.
22. Borrebaeck CAK Wingren C (2007) High throughput proteomics using antibody microarrays: an update. Expert Rev Mol Diagn 7, 673 686.
23. Haab BB (2005) Antibody arrays in cancer research. Mol Cell Proteomics 4, 377 383.
24. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA Petricoin EF III. (2007) Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 7, 625 633.
25. Winters M, Dabir B, Yu M Kohn EC (2007) Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics 22, 4066 4068.
26. Gromov P, Celis JE, Gromova I, Rank F, Timmermans-Wielinga V Moreira JMA (2008) A single lysis solution for the analysis of tissue samples by different proteomic technologies. Mol Oncol 2, 368 379.
27. Ghatnekar-Nilsson S, Dexlin L, Wingren C, Montelius L Borrebaeck CAK (2007) Design of atto-vial based recombinant antibody arrays combined with a planar waveguide detection system. Proteomics 7, 540 547.
28. Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF III., Liotta LA Abati A (2007) The needle in the haystack:application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer Cytopathol 111, 173 184.